On February 2, 2017 – ARCH Venture Partners and Versant Ventures
reported the launch of Vividion Therapeutics, Inc., a biotechnology company
focused on developing innovative therapeutics that treat major unmet clinical needs
using the first platform for proteome-wide ligand and target discovery. ARCH and
Versant co-led today’s $50 million Series A financing and were joined by founding
investor Cardinal Partners (Press release, Vividion Therapeutics, FEB 2, 2017, View Source [SID1234520718]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vividion Therapeutics has advanced a novel drug discovery platform that applies
chemical proteomics to expand the druggable proteome and address difficult targets to
bring new, transformative treatments to patients with serious illnesses. Making
accessible the broad set of proteins expressed in human cells, the company’s cutting
edge platform was spun out of the lab of Ben Cravatt, Professor at The Scripps
Research Institute in La Jolla, Calif.
In conjunction with the financing, Tom Daniel will join the Board as Executive Chairman.
"This Series A financing reflects deep commitment to Vividion Therapeutics’ approach
to transform chemical drug discovery and development," stated Dr. Daniel. "The
founders, experienced team and platform are ruthlessly focused on the accelerated
delivery of impactful drugs to serve patients. The platform expands the definition of
druggability on mechanism in serious illnesses, while delivering new routes to address
highly validated disease targets."
Vividion Therapeutics Novel Scientific Approach
Conventional drug discovery is target-centric;; a compound library is screened using a
target-specific assay and high-affinity binding ligands are optimized to develop a drug
candidate. This approach is limited, as research is performed in artificial systems that
fail to account for native protein structure, context and function. Further, conventional
target-specific assays are applied to a narrow subset of the proteome and selectivity is
assessed later in development.
In contrast, Vividion Therapeutics assesses with high precision and broad coverage
protein-drug candidate interactions in native biological systems. This eliminates artifacts
and creates proteome-wide drug interaction maps for simultaneous target engagement
and global selectivity profiling. Through novel chemistry, Vividion Therapeutics’ platform
allows efficient, accelerated optimization of hit fragments into drug candidates. The
company has a robust intellectual property estate that includes the assignment of
numerous, heretofore unrecognized, druggable sites in the human proteome.
"The Vividion Therapeutics’ platform allows human biology to fundamentally drive the
selection of drug targets and to create entry points for targets previously considered to
be undruggable," said Kristina Burow, Managing Director at ARCH. "The team at
Vividion Therapeutics has created a novel platform based on chemical proteomics and
modern synthetic chemistry that will radically expand the druggability of the human
proteome. We believe this will lead to innovative therapeutics that have the ability to
significantly benefit patients."
Vividion Therapeutics Co-Founders
The Vividion Therapeutics founding team includes:
• Benjamin F. Cravatt III, Ph.D., Professor and Co-Chair, Department of Molecular
Medicine, the Skaggs Institute for Chemical Biology at The Scripps Research
Institute
• Phil S. Baran, Ph.D., Professor, Darlene Shiley Professor of Chemistry,
Department of Chemistry, the Skaggs Institute for Chemical Biology at The
Scripps Research Institute
• Jin-Quan Yu, Ph.D., Frank and Bertha Hupp Professor of Chemistry,
Department of Chemistry, The Scripps Research Institute
• John K. Clarke, Managing General Partner, Cardinal Partners
Vividion Therapeutics Board of Directors
The Vividion Therapeutics scientific team is complemented by a Board of Directors that
has significant experience in creating, leading and growing biopharmaceutical
companies. In addition to Dr. Cravatt and Mr. Clarke, they include:
• Tom Daniel, M.D., Executive Chairman of the Board, formerly President, Global
Research and Early Development, Celgene Corporation
• Kristina Burow, Managing Director, ARCH Venture Partners
• Tom Woiwode, Ph.D., Managing Director, Versant Ventures
• Paul Schimmel, Ph.D., Professor, Department of Cell and Molecular Biology,
Department of Chemistry, The Skaggs Institute for Chemical Biology at The
Scripps Research Institute
About Vividion Therapeutics
Vividion Therapeutics is a biotechnology company focused on developing innovative
therapeutics that treat major unmet clinical needs using the first platform for proteome-
wide ligand and target discovery. Headquartered in San Diego, CA, Vividion
Therapeutics is a private, biotechnology company founded in 2014 with seed financing
from Cardinal Partners as a spin out from the labs of Dr. Benjamin Cravatt, Dr. Phil
Baran and Dr. Jin-Quan Yu at TSRI. In 2017, Vividion launched with $50 million in
Series A financing from ARCH Venture Partners, Versant Ventures and founding
investor Cardinal Partners. For more information, please visit www.vividion.com.
About ARCH Venture Partners
ARCH Venture Partners, one of the largest early stage technology venture firms in the
U.S., invests in seed and early stage advanced technology companies. ARCH enjoys
special recognition as a leader in the commercialization of technologies developed at
academic institutions, corporate research labs and national laboratories. Now in its 30th
year, ARCH has over $2.5 billion in committed capital through nine venture funds, and
has co-founded and provided initial investments for over 200 companies. For more
information, please visit View Source
About Versant Ventures
Versant Ventures is a leading healthcare investment firm committed to helping
exceptional entrepreneurs build the next generation of great healthcare companies. The
firm invests across the healthcare sector and at all stages of company development,
with an emphasis on the discovery and development of novel therapeutics. With $2.3
billion under management and offices in North America and Europe, Versant has built a
team with deep investment, operating, and scientific expertise that enables a hands-on
approach to company building. Since the firm’s founding in 1999, more than 65 Versant
companies have achieved successful acquisitions or IPOs. For more information,
please visit www.versantventures.com.
About Cardinal Partners
Cardinal Partners, founded in 1996, is one of the leading venture capital partnerships
focused exclusively on healthcare investing. Cardinal specializes in early-stage
financing rounds. As veteran company-builders, over the course of their careers, the
Cardinal Partners team has invested in over 100 growth companies. Companies funded
by Cardinal have a cumulative market valuation exceeding $20 billion. Cardinal’s
investors include university endowments, foundations, pension funds, banks, and
insurance companies. Cardinal currently manages funds totaling $400 million. For more
information, please visit View Source